Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medicine should be determined according to the patient’s current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients).
2. Patients receiving metformin:
- The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose.
- Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
Improvement of glycemic control in patients with type 2 diabetes mellitus
Type 2 diabetes
difficulty controlling blood sugar
View approved original textHide original text
This medicine is used to help improve blood sugar control in patients with type 2 diabetes alongside dietary and exercise therapy. It is particularly administered when previous diabetes medication treatment was not received or when adequate blood sugar control cannot be achieved with metformin or sitagliptin alone. Additionally, it can be combined with other medications like metformin, sulfonylurea, thiazolidinedione, or insulin when blood sugar control is insufficient, to more effectively manage blood sugar. This medicine assists in improving blood sugar control across various treatment stages.
How to take
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medicine should be determined according to the patient’s current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients).
2. Patients receiving metformin:
- The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose.
- Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
Precautions
This medicine contains two components: sitagliptin and metformin.
Firstly, sitagliptin is a medication that helps in blood sugar control and may cause hypersensitivity reactions, so if allergic symptoms arise, administration should be stopped immediately.
In particular, serious allergic reactions such as anaphylaxis, angioedema, and severe skin disorders can occur within 3 months of administration, so caution is necessary.
Furthermore, sitagliptin poses a risk of acute pancreatitis, inflammation of the pancreas, and if symptoms such as abdominal pain, vomiting, and loss of appetite occur during treatment, one should consult a doctor immediately.
Metformin helps lower blood sugar but may rare instances cause a severe side effect called lactic acidosis.
Lactic acidosis manifests as muscle pain, difficulty breathing, fatigue, and abdominal pain, and should these symptoms arise, one must discontinue the medication and seek medical attention immediately.
This medicine should not be administered to patients with moderate or severe impaired renal function, severe infections, acute myocardial infarction, heart failure, or to women who are pregnant or breastfeeding.
Moreover, before and after examinations using iodinated contrast agents, medication should be suspended for a certain period to prevent worsening kidney function, and kidney function should be checked before resuming treatment.
During treatment, the risk of hypoglycemia exists, so one must not skip or have irregular meals, and care should be taken when engaging in vigorous exercise.
This medicine may cause gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain), headaches, and upper respiratory tract infections.
Particularly, caution is required as the risk of hypoglycemia may increase when used with other hypoglycemic agents like insulin or sulfonylurea.
Regular monitoring of kidney function and blood tests should be conducted before and during treatment, and since vitamin B12 deficiency may occur, supplementation may be necessary.
Alcohol may increase the risk of side effects from this medicine, so it is important to avoid excessive drinking while taking it.
If surgery is forthcoming, or if there is a severe infection or state of dehydration, medication should be temporarily suspended, and should be restarted after recovery as directed by a physician.
Finally, it is crucial to see healthcare personnel immediately if any unusual symptoms occur during treatment with this medicine.
Side effects
Anaphylaxis
Not everyone experiences these, and they can vary from person to person.
Storage
This medicine should be stored in a tightly sealed container to prevent air ingress, and it is best kept at room temperature between 1 and 30 degrees Celsius.
Therefore, it is important not to place it in excessively hot or cold locations.
Appearance and packaging
Appearance
Pink oval film-coated tablets
Package unit
30 tablets/box[(10 tablets/PTP×3)]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.